Your cup runneth over this week. The earlier issue was egocentric, so I want to give readers something that is not a cry for attention. I mean, I don’t live in Memphis, if you catch my drift (or even if you don’t).
It was only a matter of time before the lawyers latched onto GLP-1 drugs as a profit-maker. I mean, why not? Everybody else has had his shot at it. Now the game progresses to the bureaucratic chaos phase. Read on to see what our plaintiff bar friends have up their collective sleeves.
Following the feature article on GLP-1 lawsuits, I’ll share a very British warning you you. What are they warning King Charles’ subjects about? Well, you guessed it: GLP-1s. Finally, yet another instance of Bullshit Corner disdains a vacuous study relating tap water to high blood pressure. You’re not going to want to believe that someone got grant funds for that sparkling bit of low-value observational research.
You’re already looking at the phony TV ad below, I know, so I’ll jump right in.
How the Plaintiff Bar Is Mining the GLP-1 Craze for Fun and Profit
Every gold rush has three phases.
First, someone discovers something valuable. Second, capital pours in. Third, the lawyers show up with shovels and start digging sideways.
Welcome to Phase Three of the GLP-1 era.
Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound—manufactured by Novo Nordisk and Eli Lilly—have done something modern medicine almost never does: they work. Not perfectly, not without tradeoffs, but meaningfully. They lower A1c, reduce weight, and reduce cardiovascular and kidney risk. And yes, they act on the gastrointestinal tract, because that is where incretin biology lives. Amazing revelation, I know.
That was Phase One.
Phase Two: Expansion
Phase Two was predictable. Massive demand, aggressive marketing, social-media hysteria, off-label prescribing, compounded knockoffs, med spas run by people whose medical training appears to consist of a laminated badge, an Instagram account, and access to an on-line doctor in India. Money everywhere. Real money.
Then, as I wrote last week in The GLP-1 Dietary Revolution, the food, supplement, and wellness industries wasted no time slapping “GLP-1 friendly” labels on anything that would hold still long enough for a marketing photo. Protein bars, shakes, frozen meals, fiber powders, hydration potions—entire product lines suddenly discovered an intimate, lifelong relationship with incretin biology. None of this was regulated. None of it was clinically validated. All of it was monetized.
This was Phase Two: secondary capitalization. Once a therapy becomes culturally dominant, every adjacent industry shows up with a hand out. The supplement industry in particular—long accustomed to operating in the regulatory shadows—saw GLP-1 users as a captive audience with disposable income and chronic anxiety. That anxiety was then helpfully amplified by influencers, clickbait headlines, and wellness grifters warning that without the right add-ons, your expensive injectable miracle might somehow “fail.”
Phase Three: The Sharks Arrive
That atmosphere matters, because it set the stage for Phase Three. When consumers are primed to believe they are both fragile and misled, litigation becomes inevitable. The plaintiff bar never misses an major opportunity to monetize by stirring a steaming pot of deep-pocketed corporations and small guy misfortunes.
Welcome to Phase Three: the plaintiff bar smells blood in the water. And it’s going to get bloodier.
As of late January 2026, more than 3,000 lawsuits have been filed against GLP-1 manufacturers. This is no longer about a few genuinely injured patients seeking redress. This is now a full-blown mass-tort industrial operation. Intake websites, TV ads, social media funnels, and law firms that have never seen a stomach they didn’t want to paralyze—on contingency.
See You in Court: The Allegations
The legal claims follow a familiar script:
- Failure to warn,
- Deceptive marketing,
- Downplayed risks, and, of course,
- Corporate greed.
The alleged injuries cluster into three buckets:
First, severe gastrointestinal complications—gastroparesis, ileus, and prolonged vomiting. These are real conditions. They are also conditions that have always been discussed in GLP-1 labeling, physician education, and FDA reviews. The idea that slowing gastric emptying might—brace yourself—slow gastric emptying is apparently now a legal revelation.
Second, vision loss, specifically NAION, a rare ischemic optic neuropathy that ophthalmologists have been debating causality on for decades. Correlation is not causation, but correlation plus a sympathetic jury equals a settlement spreadsheet.
Third, marketing claims, alleging that weight-loss enthusiasm somehow negated decades of informed consent doctrine. Apparently, if enough people want a drug, lawyers can argue that nobody really consented to it. Wasn’t really their idea. You get it.
Far removed from good science, this amounts to narrative construction, painstakingly contrived to resonate with juries.
Enter the MDL Machine
To keep the litigation “efficient” (read: scalable), the cases have been herded into Multidistrict Litigation (MDL) in the Eastern District of Pennsylvania.
MDL 3094 handles the GI claims.
MDL 3163 handles the NAION claims.
If you’ve followed mass torts before—Roundup, Vioxx, opioids, talc, mesh—you know the playbook. Consolidate. Delay. Leak scary numbers to the press. Float hypothetical settlement ranges. Repeat until shareholders blink. Oy vey is mir!
Experts are already whispering about potential settlements ranging from $150,000 to $700,000 per plaintiff, depending on injury severity. What’s driving the numbers is not actual liability, but probabilistic jury acquiescence.
And no, the lawyers are not paid by the hour for this valuable civic service.
Expansion Pack: Everyone Gets Sued
Predictably, the litigational blast radius is growing.
Manufacturers are suing compounding pharmacies and med spas for selling “research-grade” semaglutide and tirzepatide—often sourced from god-knows-where, mixed by god-knows-who, and injected into economically-minded patients who think “USP” is a yoga pose.
Meanwhile, state attorneys general in places like Connecticut and Texas have decided this party looks fun and have piled on with their own actions, alleging kickbacks and deceptive distribution practices.
At this point, the only people not being sued are the TikTok influencers who convinced half the country that peptides are a lifestyle choice.
Give it time.
The Buchanan Moment: From Innovation to Racket
Here’s where the Buchananistic progression matters.
We started with genuine medical innovation, then moved to commercialization and excess. We have now arrived at the racket phase.
The plaintiff bar does not innovate. It neither heals nor prevents harm. It extracts value after the fact, using the legal system as a leverage multiplier. When it “wins,” patients do not get safer drugs faster. They get checks years later, minus fees. Manufacturers respond by raising prices, narrowing indications, and practicing defensive labeling that helps no one.
Who pays? Patients, insurers, taxpayers, and future patients who never get the next generation of therapies because the liability risk killed them in utero.
Big Pharma may be making money, but don’t kid yourself: the contingency-fee class wants its cut — and it always sucks out its share first.
Which brings us to the next logical step in this entropy cascade.
Phase Four: Government Sues Government
This phase is still theoretical—for now—but it is entirely consistent with how late-stage institutional decay works.
Once private-sector defendants have been bled sufficiently, attention will shift inward. Regulatory agencies, having failed to prevent confusion, overpromising, under-education, and media panic, will discover that the safest place to point the finger is sideways.
Picture it:
- The CDC releases guidance suggesting long-term population risks were underestimated.
- The FDA responds that all labeling was adequate and science-based.
- Congressional hearings ensue.
- Inspectors general sharpen knives.
- States file suit claiming federal preemption failures.
- Federal agencies counterclaim jurisdictional overreach.
At that point, the legal profession achieves peak efficiency: taxpayer-funded agencies suing each other with taxpayer-funded lawyers, while taxpayer-funded courts referee the spectacle. Money circulates. Nothing improves.
This is the mythical Phase Four, where entropy completes the loop. Innovation is long gone. Accountability is a side-show. Everyone is technically “doing something,” and no one is actually solving the problem that started it all: how to deploy powerful therapies rationally, transparently, and without turning them into cultural moral panics.
If that sounds far-fetched, recall that we already live in a world where hospitals sue insurers, insurers sue states, states sue the federal government, and the federal government sues itself via administrative law. Adding GLP-1s to that bonfire is consistency rather than escalation.
So yes, you catch my drift—and unfortunately, so does everyone else who has watched a functional system slide headlong into the racket phase.
Final Thought
Indeed, I do not deny that some patients have been harmed. They deserve care, honesty, and compensation where causality is real and proven. But what we are watching now perverts any essence of justice into opportunism.
GLP-1s didn’t create this system. They just wandered into it—effective enough to be valuable, popular enough to be profitable, and complex enough to be litigated to death. The plaintiff bar never misses such a juicy opportunity.
And Peptide Purgatory now has followed the GLP-1 morass down the fiery staircase to the Seven Rings of Legal Hell.
The British Are Very Concerned (Again)
When the UK government clears its throat, it does so politely, formally, and with a footnote. This week’s contribution comes from the Medicines and Healthcare products Regulatory Agency (MHRA), which has issued a sternly worded update reminding everyone that GLP-1 receptor agonists can, in rare cases, cause acute pancreatitis—including necrotising and fatal forms.
This announcement has already begun its transatlantic journey, stripped of nuance and inflated by social media into something resembling “GLP-1s melt your pancreas.” That is not what the MHRA said—but let’s translate this into plain English anyway.
What Actually Happened
The MHRA reviewed post-marketing safety data covering 2007 through October 2025. During that period, roughly 25.4 million packs of GLP-1 drugs were dispensed in the UK. Against that backdrop, regulators received 1,296 reports of pancreatitis of all flavors—acute, chronic, autoimmune, hemorrhagic, necrotising, and otherwise unpleasant.
Of those:
- 19 cases were fatal
- 24 were necrotising
That is not zero. It is also not an epidemic. It is pharmacovigilance doing exactly what pharmacovigilance is supposed to do: flag rare but serious adverse events in widely used drugs.
The MHRA’s conclusion was not “panic.” It was “tighten the warnings so clinicians don’t miss the signal.”
The Regulatory Subtext (Read This Slowly)
Pancreatitis has always been a known risk with GLP-1 drugs. This is not a discovery. What changed is volume. When millions more people take a medication—many privately, many off-label, many without robust continuity of care—you inevitably surface edge cases that were statistically invisible before.
The MHRA’s real concern is not that GLP-1s suddenly became dangerous. It’s that pancreatitis can be hard to distinguish early on from the garden-variety nausea, vomiting, and abdominal discomfort that GLP-1s commonly cause.
Translation: if someone shows up with persistent, radiating abdominal pain and is quietly injecting semaglutide obtained from a wellness clinic that doesn’t talk to their GP, clinicians need to know that fact before they send the patient home with antacids.
This is less about the drug and more about the ecosystem.
The Quiet Line That Matters Most
Buried in the advisory is the line lawyers will soon laminate:
“Privately prescribed GLP-1s and GLP-1/GIPs may not appear on the patient’s medical history.”
There it is. Phase Two meets Phase Three.
Unreported use. Fragmented care. Parallel prescribing systems. And now regulators politely reminding physicians to ask the obvious question: “Are you taking anything injectable that you didn’t bother to tell me about?”
Expect this sentence to appear verbatim in future complaints.
What the MHRA Did Not Say
They did not:
- withdraw the drugs,
- restrict prescribing,
- recommend discontinuation absent symptoms, or
- claim causality was newly established.
They strengthened labeling and told clinicians to stay alert. That’s it.
In regulatory terms, this is routine maintenance—not a five-alarm fire.
Why This Still Matters (Unfortunately)
This update lands at exactly the wrong cultural moment. We are already deep into Phase Three of the GLP-1 cycle, where litigation thrives on ambiguity and regulators’ cautionary language is recast as proof of malfeasance.
To the MHRA, this is a safety bulletin. To the plaintiff bar, it’s Exhibit A, freshly minted in bureaucratic prose.
And to the internet, it’s yet another reason to believe that modern medicine is lying to you, unless it comes in capsule form sold by a podcast host.
Bottom Line
The British government did what regulators are supposed to do: review data, acknowledge rare but severe outcomes, tighten warnings, and move on. No hysteria, no theatrics, no press conference with PowerPoint slides of flaming pancreases. Which, of course, means the rest of the world will now overreact accordingly.
And, of course, the lawyers are licking their chops.
BULLSHIT CORNER: Your Tap Water Is Trying to Kill You (Again)
This week’s entry arrives courtesy of a MedPage Today headline that strongly suggests your kitchen faucet is a stealth hypertension delivery system. According to the story, “some tap water may raise blood pressure,” with a risk supposedly comparable to low physical activity.
If that comparison didn’t immediately trip your bullshit detector, it may be time to recalibrate.
The underlying study is a meta-analysis of observational data reporting a roughly 3 mm Hg increase in systolic and ~3 mm Hg increase in diastolic blood pressure among people exposed to higher-salinity drinking water. At an individual level, that magnitude lives comfortably within normal day-to-day variability — hydration status, caffeine intake, stress, or whether the cuff was applied by someone who understands anatomy.
Population-Level Impact
To keep the narrative afloat, the authors invoke the epidemiologist’s all-purpose flotation device: population-level impact. Translation: “Yes, this is clinically trivial for you, but if we multiply it by a very large number of people and assume no competing variables, it starts to look scary.”
The rhetorical peak comes when water salinity is likened to low physical activity as a cardiovascular risk factor. This is category error, not insight. Physical activity affects blood pressure, insulin sensitivity, endothelial function, inflammation, body composition, and mortality. Salty groundwater nudges diastolic pressure by a couple of millimeters. These are not comparable phenomena, no matter how aggressively one squints.
In Dhaka, Don’t Drink the Water
Geography, inconveniently, does most of the work. The strongest signals come from coastal South Asia — particularly Bangladesh — where groundwater sodium levels can exceed 2,600 mg/L due to saltwater intrusion. That is not “tap water” as experienced in North America or Europe; that is lightly diluted brine. Unsurprisingly, when analyses are stratified, the systolic blood pressure signal vanishes outside Asia.
The One You Care About
The U.S. subgroup — the one readers here might reasonably care about — shows a ~1.9 mm Hg increase in diastolic pressure and no systolic effect at all. This is statistical chaff. No clinician is altering management based on this delta, and no guideline committee is sharpening pencils.
It’s All Sodium to Me
The mechanistic explanations rehash sodium physiology we have known for decades, while quietly sidestepping the obvious: in developed countries, 85–95% of sodium intake comes from food, not drinking water. Even the World Health Organization declines to set health-based sodium limits for drinking water, citing lack of concern at typical concentrations.
And the tell that gives the whole thing away: no convincing association with coronary heart disease or stroke. Blood pressure is a surrogate. Outcomes are the point. When the signal dies at the surrogate level, restraint is advised.
Technically true, contextually abused, and editorially irresponsible. If your blood pressure is elevated, the problem is almost certainly your diet, your waistline, your activity level, your sleep, your kidneys, or your genetics — not your municipal water supply. Blaming the faucet instead of the potato chips is misdirection, not preventive medicine.
Peptide Purgatory, published more or less weekly (whenever I feel like it), mixes one old fart’s ongoing experiment with GLP-1s, metabolism, and medical modernity with a veritable plethora of opinions on the subject. Side effects may include sarcasm, elevated skepticism, and mild tachycardia. Ask your doctor whether Peptide Purgatory is right for you!
For an annotated catalog of all my Peptide Purgatory and Mounjaro updates, visit my Mounjaro Update Catalog page.
Share this:
Discover more from The Nittany Turkey
Subscribe to get the latest posts sent to your email.
